HeartBeam remains in a high-risk, pre-revenue developmental stage characterized by consistent quarterly operating losses of approximately $5 million and a rapidly depleting capital base.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.10-16.3% vs -$0.09 | $100,000-32.2% vs $147,400 |
Q2 2026 May 13, 2026 | -$0.12+14.3% vs -$0.14 | — vs $149,750 |
Q2 2026 Mar 12, 2026 | -$0.14-7.7% vs -$0.13 | — vs $1M |
Q4 2025 Nov 13, 2025 | -$0.15+6.3% vs -$0.16 | — vs $875,000 |
SANTA CLARA, Calif.--(BUSINESS WIRE)--HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome.
Medical technology provider HeartBeam, Inc. (NASDAQ:BEAT) received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its at-home cardiac assessment tool.
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment.
Benchmark BEAT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for HeartBeam, Inc. (BEAT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.40 | $22.31M | -1.05 | — | — | -686.78% | — | |
| $27.70 | $74.56M | 1.17 | 12.07% | 17.17% | 136.07% | — | |
| $1.93 | $112.69M | -0.96 | 1057.12% | -1302.78% | -122.85% | — | |
| $676.04 | $53.33B | 45.20 | 10.42% | 25.36% | 71.18% | — | |
| $90.22 | $2.96B | -77.39 | 26.24% | -4.52% | -22.8% | — | |
| $6.37 | $1.7B | -31.61 | 18.96% | -43.56% | -28.22% | — |
HeartBeam, Inc. (BEAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
HeartBeam, Inc. (BEAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 3, 2026·SEC
Jul 2, 2026·SEC
Get notified when BEAT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HeartBeam, Inc. (BEAT) stock FAQ — growth, dividends, profitability & financials explained
No. HeartBeam, Inc. (BEAT) reported a net loss of $20.3M over the trailing twelve months.
HeartBeam, Inc. (BEAT) had a return on equity (ROE) of -686.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
HeartBeam, Inc. (BEAT) had negative free cash flow of $14.0M over the trailing twelve months.
